Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review.
Cardiovascular risk
Metabolic dysfunction-associated steatotic liver disease
Metabolic-associated fatty liver disease
Nonalcoholic fatty liver disease
Journal
Cardiovascular diabetology
ISSN: 1475-2840
Titre abrégé: Cardiovasc Diabetol
Pays: England
ID NLM: 101147637
Informations de publication
Date de publication:
28 Sep 2024
28 Sep 2024
Historique:
received:
12
06
2024
accepted:
09
09
2024
medline:
29
9
2024
pubmed:
29
9
2024
entrez:
28
9
2024
Statut:
epublish
Résumé
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously termed nonalcoholic fatty liver disease (NAFLD), poses a significant global health challenge due to its increasing prevalence and strong association with cardiovascular disease (CVD). This comprehensive review summarizes the current knowledge on the MASLD-CVD relationship, compares analysis of how different terminologies for fatty liver disease affect cardiovascular (CV) risk assessment using different diagnostic criteria, explores the pathophysiological mechanisms connecting MASLD to CVD, the influence of MASLD on traditional CV risk factors, the role of noninvasive imaging techniques and biomarkers in the assessment of CV risk in patients with MASLD, and the implications for clinical management and prevention strategies. By incorporating current research and clinical guidelines, this review provides a comprehensive overview of the complex interplay between MASLD and cardiovascular health.
Identifiants
pubmed: 39342178
doi: 10.1186/s12933-024-02434-5
pii: 10.1186/s12933-024-02434-5
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
346Informations de copyright
© 2024. The Author(s).
Références
Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84.
pubmed: 26707365
doi: 10.1002/hep.28431
Targher G, Byrne CD, Tilg H. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut. 2024;73(4):691–702.
pubmed: 38228377
Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, Zelber-Sagi S, Wai-Sun Wong V, Dufour JF, Schattenberg JM, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202–9.
pubmed: 32278004
doi: 10.1016/j.jhep.2020.03.039
Gofton C, Upendran Y, Zheng MH, George J. MAFLD: how is it different from NAFLD? Clin Mol Hepatol. 2023;29(Suppl):S17–31.
pubmed: 36443926
doi: 10.3350/cmh.2022.0367
Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, Romero D, Abdelmalek MF, Anstee QM, Arab JP, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79(6):1542–56.
pubmed: 37364790
doi: 10.1016/j.jhep.2023.06.003
Diehl AM, Day C. Cause, Pathogenesis, and treatment of Nonalcoholic Steatohepatitis. N Engl J Med. 2017;377(21):2063–72.
pubmed: 29166236
doi: 10.1056/NEJMra1503519
Kaya E, Yilmaz Y. Metabolic-associated fatty liver Disease (MAFLD): a multi-systemic disease beyond the liver. J Clin Transl Hepatol. 2022;10(2):329–38.
pubmed: 35528971
doi: 10.14218/JCTH.2021.00178
Tsutsumi T, Nakano D, Hashida R, Sano T, Kawaguchi M, Amano K, Kawaguchi T. The Inter-organ Crosstalk reveals an inevitable link between MAFLD and Extrahepatic diseases. Nutrients 2023, 15(5).
Adams LA, Anstee QM, Tilg H, Targher G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut. 2017;66(6):1138–53.
pubmed: 28314735
doi: 10.1136/gutjnl-2017-313884
Li AA, Ahmed A, Kim D. Extrahepatic manifestations of nonalcoholic fatty liver disease. Gut Liver. 2020;14(2):168–78.
pubmed: 31195434
doi: 10.5009/gnl19069
Lee HH, Lee HA, Kim EJ, Kim HY, Kim HC, Ahn SH, Lee H, Kim SU. Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease. Gut. 2024;73(3):533–40.
pubmed: 37907259
Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol. 2016;65(3):589–600.
pubmed: 27212244
doi: 10.1016/j.jhep.2016.05.013
Janssen A, Grobbee DE, Dendale P. Non-alcoholic fatty liver disease, a new and growing risk indicator for cardiovascular disease. Eur J Prev Cardiol. 2020;27(10):1059–63.
pubmed: 31801050
doi: 10.1177/2047487319891783
Francque SM, van der Graaff D, Kwanten WJ. Non-alcoholic fatty liver disease and cardiovascular risk: pathophysiological mechanisms and implications. J Hepatol. 2016;65(2):425–43.
pubmed: 27091791
doi: 10.1016/j.jhep.2016.04.005
Stahl EP, Dhindsa DS, Lee SK, Sandesara PB, Chalasani NP, Sperling LS. Nonalcoholic fatty liver disease and the heart: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73(8):948–63.
pubmed: 30819364
doi: 10.1016/j.jacc.2018.11.050
Choudhary NS, Duseja A. Screening of cardiovascular disease in nonalcoholic fatty liver disease: whom and how? J Clin Exp Hepatol. 2019;9(4):506–14.
pubmed: 31516267
pmcid: 6728527
doi: 10.1016/j.jceh.2019.02.005
Kasper P, Martin A, Lang S, Kutting F, Goeser T, Demir M, Steffen HM. NAFLD and cardiovascular diseases: a clinical review. Clin Res Cardiol. 2021;110(7):921–37.
pubmed: 32696080
doi: 10.1007/s00392-020-01709-7
Pan Z, Shiha G, Esmat G, Mendez-Sanchez N, Eslam M. MAFLD predicts cardiovascular disease risk better than MASLD. Liver Int 2024.
Ciardullo S. The MAFLD-MASLD debate: does cardiovascular risk prediction define the winner? Liver Int. 2024;44(7):1564–6.
pubmed: 38886912
doi: 10.1111/liv.15950
Ramirez-Mejia MM, Jimenez-Gutierrez C, Eslam M, George J, Mendez-Sanchez N. Breaking new ground: MASLD vs. MAFLD-which holds the key for risk stratification? Hepatol Int. 2024;18(1):168–78.
pubmed: 38127259
doi: 10.1007/s12072-023-10620-y
Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the study of liver diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55(6):2005–23.
pubmed: 22488764
doi: 10.1002/hep.25762
Cheng YM, Wang CC, Kao JH. Metabolic associated fatty liver disease better identifying patients at risk of liver and cardiovascular complications. Hepatol Int. 2023;17(2):350–6.
pubmed: 36471232
doi: 10.1007/s12072-022-10449-x
Xu X, Zhou X, Tian T, Ding Y, Yu C, Zhao W, Wang X, Lu J, Guo W, Jiang L, et al. Comparison of clinical characteristics and outcomes of MAFLD and NAFLD in Chinese Health examination populations. J Clin Transl Hepatol. 2023;11(4):777–86.
pubmed: 37408819
pmcid: 10318292
Hagstrom H, Vessby J, Ekstedt M, Shang Y. 99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical. J Hepatol. 2024;80(2):e76–7.
pubmed: 37678723
doi: 10.1016/j.jhep.2023.08.026
Kang MK, Song J, Loomba R, Park S, Tak W, Kweon Y, Lee Y, Park JG. Comparative associations of MASLD and MAFLD with the presence and severity of coronary artery calcification. 2024.
Ciardullo S, Mantovani A, Morieri ML, Muraca E, Invernizzi P, Perseghin G. Impact of MASLD and MetALD on clinical outcomes: a meta-analysis of preliminary evidence. Liver Int. 2024;44(8):1762–7.
pubmed: 38597738
doi: 10.1111/liv.15939
Choe HJ, Moon JH, Kim W, Koo BK, Cho NH. Steatotic liver disease predicts cardiovascular disease and advanced liver fibrosis: a community-dwelling cohort study with 20-year follow-up. Metabolism. 2024;153:155800.
pubmed: 38266957
doi: 10.1016/j.metabol.2024.155800
Aedh AI, Alshahrani MS, Huneif MA, Pryme IF, Oruch R. A glimpse into milestones of insulin resistance and an updated review of its management. Nutrients 2023, 15(4).
Pal SC, Mendez-Sanchez N. Insulin resistance and adipose tissue interactions as the cornerstone of metabolic (dysfunction)-associated fatty liver disease pathogenesis. World J Gastroenterol. 2023;29(25):3999–4008.
pubmed: 37476582
pmcid: 10354585
doi: 10.3748/wjg.v29.i25.3999
Zhao J, Wu Y, Rong X, Zheng C, Guo J. Anti-lipolysis Induced by insulin in diverse pathophysiologic conditions of adipose tissue. Diabetes Metab Syndr Obes. 2020;13:1575–85.
pubmed: 32494174
pmcid: 7227813
doi: 10.2147/DMSO.S250699
Kosmas CE, Bousvarou MD, Kostara CE, Papakonstantinou EJ, Salamou E, Guzman E. Insulin resistance and cardiovascular disease. J Int Med Res. 2023;51(3):3000605231164548.
pubmed: 36994866
doi: 10.1177/03000605231164548
Yang K, Song M. New Insights into the pathogenesis of metabolic-associated fatty liver disease (MAFLD): gut-liver-heart crosstalk. Nutrients 2023, 15(18).
Zhao J, Liu L, Cao YY, Gao X, Targher G, Byrne CD, Sun DQ, Zheng MH. MAFLD as part of systemic metabolic dysregulation. Hepatol Int 2024.
Burger K, Jung F, Baumann A, Brandt A, Staltner R, Sanchez V, Bergheim I. TNFalpha is a key trigger of inflammation in diet-induced non-obese MASLD in mice. Redox Biol. 2023;66:102870.
pubmed: 37683301
pmcid: 10493600
doi: 10.1016/j.redox.2023.102870
Zhu M, Lei L, Zhu Z, Li Q, Guo D, Xu J, Chen J, Sha H, Zhang X, Yang X, et al. Excess TNF-alpha in the blood activates monocytes with the potential to directly form cholesteryl ester-laden cells. Acta Biochim Biophys Sin (Shanghai). 2015;47(11):899–907.
pubmed: 26373842
doi: 10.1093/abbs/gmv092
Rafaqat S, Gluscevic S, Mercantepe F, Rafaqat S, Klisic A. Interleukins: pathogenesis in non-alcoholic fatty liver disease. Metabolites 2024, 14(3).
Duan Y, Pan X, Luo J, Xiao X, Li J, Bestman PL, Luo M. Association of inflammatory cytokines with non-alcoholic fatty liver disease. Front Immunol. 2022;13:880298.
pubmed: 35603224
pmcid: 9122097
doi: 10.3389/fimmu.2022.880298
Ngwa DN, Pathak A, Agrawal A. IL-6 regulates induction of C-reactive protein gene expression by activating STAT3 isoforms. Mol Immunol. 2022;146:50–6.
pubmed: 35430542
pmcid: 9811655
doi: 10.1016/j.molimm.2022.04.003
Medina-Leyte DJ, Zepeda-Garcia O, Dominguez-Perez M, Gonzalez-Garrido A, Villarreal-Molina T, Jacobo-Albavera L. Endothelial dysfunction, inflammation and coronary artery disease: potential biomarkers and promising therapeutical approaches. Int J Mol Sci. 2021;22(8).
Castillo-Nunez Y, Almeda-Valdes P, Gonzalez-Galvez G, Arechavaleta-Granell MDR. Metabolic dysfunction-associated steatotic liver disease and atherosclerosis. Curr Diab Rep. 2024;24(7):158–66.
pubmed: 38700793
doi: 10.1007/s11892-024-01542-6
Ma Y, Lee G, Heo SY, Roh YS. Oxidative stress is a key modulator in the development of nonalcoholic fatty liver disease. Antioxid (Basel) 2021, 11(1).
Batty M, Bennett MR, Yu E. The role of oxidative stress in atherosclerosis. Cells 2022, 11(23).
Munzel T, Camici GG, Maack C, Bonetti NR, Fuster V, Kovacic JC. Impact of oxidative stress on the heart and vasculature: part 2 of a 3-Part series. J Am Coll Cardiol. 2017;70(2):212–29.
pubmed: 28683969
pmcid: 5663297
doi: 10.1016/j.jacc.2017.05.035
Colak E, Pap D. The role of oxidative stress in the development of obesity and obesity-related metabolic disorders. J Med Biochem. 2021;40(1):1–9.
pubmed: 33584134
pmcid: 7857849
doi: 10.5937/jomb0-24652
Kruger-Genge A, Blocki A, Franke RP, Jung F. Vascular endothelial cell Biology: an update. Int J Mol Sci 2019, 20(18).
Nasiri-Ansari N, Androutsakos T, Flessa CM, Kyrou I, Siasos G, Randeva HS, Kassi E, Papavassiliou AG. Endothelial Cell Dysfunction and Nonalcoholic Fatty Liver Disease (NAFLD): A Concise Review. Cells 2022, 11(16).
Andrabi SM, Sharma NS, Karan A, Shahriar SMS, Cordon B, Ma B, Xie J. Nitric oxide: physiological functions, delivery, and biomedical applications. Adv Sci (Weinh). 2023;10(30):e2303259.
pubmed: 37632708
doi: 10.1002/advs.202303259
Vairappan B. Endothelial dysfunction in cirrhosis: role of inflammation and oxidative stress. World J Hepatol. 2015;7(3):443–59.
pubmed: 25848469
pmcid: 4381168
doi: 10.4254/wjh.v7.i3.443
Gunawardena T, Merinopoulos I, Wickramarachchi U, Vassiliou V, Eccleshall S. Endothelial dysfunction and coronary vasoreactivity - A review of the history, physiology, diagnostic techniques, and clinical relevance. Curr Cardiol Rev. 2021;17(1):85–100.
pubmed: 32552654
pmcid: 8142375
doi: 10.2174/1573403X16666200618161942
Shimabukuro M. MAFLD and small dense LDL cholesterol: a mechanistic link. J Atheroscler Thromb. 2024;31(1):17–8.
pubmed: 37989291
doi: 10.5551/jat.ED247
Heeren J, Scheja L. Metabolic-associated fatty liver disease and lipoprotein metabolism. Mol Metab. 2021;50:101238.
pubmed: 33892169
pmcid: 8324684
doi: 10.1016/j.molmet.2021.101238
Virovic-Jukic L, Stojsavljevic-Shapeski S, Forgac J, Kukla M, Mikolasevic I. Non-alcoholic fatty liver disease - a procoagulant condition? Croat Med J. 2021;62(1):25–33.
pubmed: 33660958
pmcid: 7976878
doi: 10.3325/cmj.2021.62.25
Ogresta D, Mrzljak A, Cigrovski Berkovic M, Bilic-Curcic I, Stojsavljevic-Shapeski S, Virovic-Jukic L. Coagulation and endothelial dysfunction Associated with NAFLD: current status and therapeutic implications. J Clin Transl Hepatol. 2022;10(2):339–55.
pubmed: 35528987
pmcid: 9039716
doi: 10.14218/JCTH.2021.00268
Gallo G, Savoia C. New insights into endothelial dysfunction in cardiometabolic diseases: potential mechanisms and clinical implications. Int J Mol Sci 2024, 25(5).
Shabalala SC, Dludla PV, Mabasa L, Kappo AP, Basson AK, Pheiffer C, Johnson R. The effect of adiponectin in the pathogenesis of non-alcoholic fatty liver disease (NAFLD) and the potential role of polyphenols in the modulation of adiponectin signaling. Biomed Pharmacother. 2020;131:110785.
pubmed: 33152943
doi: 10.1016/j.biopha.2020.110785
Martinez-Una M, Lopez-Mancheno Y, Dieguez C, Fernandez-Rojo MA, Novelle MG. Unraveling the role of leptin in liver function and its relationship with Liver diseases. Int J Mol Sci 2020, 21(24).
Vilarino-Garcia T, Polonio-Gonzalez ML, Perez-Perez A, Ribalta J, Arrieta F, Aguilar M, Obaya JC, Gimeno-Orna JA, Iglesias P, Navarro J et al. Role of leptin in obesity, Cardiovascular Disease, and type 2 diabetes. Int J Mol Sci 2024, 25(4).
Kirichenko TV, Markina YV, Bogatyreva AI, Tolstik TV, Varaeva YR, Starodubova AV. The role of Adipokines in inflammatory mechanisms of obesity. Int J Mol Sci 2022, 23(23).
Lim S, Meigs JB. Links between ectopic fat and vascular disease in humans. Arterioscler Thromb Vasc Biol. 2014;34(9):1820–6.
pubmed: 25035342
pmcid: 4140970
doi: 10.1161/ATVBAHA.114.303035
Kozawa J, Shimomura I. Ectopic fat accumulation in pancreas and heart. J Clin Med 2021, 10(6).
Sakurai Y, Kubota N, Yamauchi T, Kadowaki T. Role of insulin resistance in MAFLD. Int J Mol Sci 2021, 22(8).
Berardo C, Di Pasqua LG, Cagna M, Richelmi P, Vairetti M, Ferrigno A. Nonalcoholic fatty liver disease and non-alcoholic steatohepatitis: current issues and future perspectives in preclinical and clinical research. Int J Mol Sci 2020, 21(24).
D’Oria R, Genchi VA, Caccioppoli C, Calderoni I, Marrano N, Biondi G, Borrelli A, Di Gioia L, Giorgino F, Laviola L. Impact of dysfunctional adipose tissue depots on the cardiovascular system. Int J Mol Sci 2022, 23(22).
Kenchaiah S, Ding J, Carr JJ, Allison MA, Budoff MJ, Tracy RP, Burke GL, McClelland RL, Arai AE, Bluemke DA. Pericardial Fat and the risk of heart failure. J Am Coll Cardiol. 2021;77(21):2638–52.
pubmed: 34045020
pmcid: 8218602
doi: 10.1016/j.jacc.2021.04.003
Zhu J, Yang Z, Li X, Chen X, Pi J, Zhuang T, Liu J, Li G, Peng S, Zhang L, et al. Association of periaortic fat and abdominal visceral fat with coronary artery atherosclerosis in Chinese middle aged and elderly patients undergoing computed tomography coronary angiography. Glob Heart. 2021;16(1):74.
pubmed: 34900565
pmcid: 8533656
doi: 10.5334/gh.1078
Cherubini A, Casirati E, Tomasi M, Valenti L. PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date. Expert Opin Ther Targets. 2021;25(12):1033–43.
pubmed: 34904923
doi: 10.1080/14728222.2021.2018418
Shen JH, Li YL, Li D, Wang NN, Jing L, Huang YH. The rs738409 (I148M) variant of the PNPLA3 gene and cirrhosis: a meta-analysis. J Lipid Res. 2015;56(1):167–75.
pubmed: 25378656
pmcid: 4274064
doi: 10.1194/jlr.M048777
Luukkonen PK, Qadri S, Lehtimaki TE, Juuti A, Sammalkorpi H, Penttila AK, Hakkarainen A, Orho-Melander M, Arola J, Yki-Jarvinen H. The PNPLA3-I148M variant confers an antiatherogenic lipid profile in insulin-resistant patients. J Clin Endocrinol Metab. 2021;106(1):e300–15.
pubmed: 33064150
doi: 10.1210/clinem/dgaa729
Huang G, Wallace DF, Powell EE, Rahman T, Clark PJ, Subramaniam VN. Gene variants implicated in steatotic liver disease: opportunities for diagnostics and therapeutics. Biomedicines 2023, 11(10).
Dongiovanni P, Petta S, Maglio C, Fracanzani AL, Pipitone R, Mozzi E, Motta BM, Kaminska D, Rametta R, Grimaudo S, et al. Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology. 2015;61(2):506–14.
pubmed: 25251399
doi: 10.1002/hep.27490
Jonas W, Schurmann A. Genetic and epigenetic factors determining NAFLD risk. Mol Metab. 2021;50:101111.
pubmed: 33160101
doi: 10.1016/j.molmet.2020.101111
Song Q, Zhang X. The role of gut-liver axis in gut microbiome dysbiosis associated NAFLD and NAFLD-HCC. Biomedicines 2022, 10(3).
Han H, Jiang Y, Wang M, Melaku M, Liu L, Zhao Y, Everaert N, Yi B, Zhang H. Intestinal dysbiosis in nonalcoholic fatty liver disease (NAFLD): focusing on the gut-liver axis. Crit Rev Food Sci Nutr. 2023;63(12):1689–706.
pubmed: 34404276
doi: 10.1080/10408398.2021.1966738
Zhen J, Zhou Z, He M, Han HX, Lv EH, Wen PB, Liu X, Wang YT, Cai XC, Tian JQ, et al. The gut microbial metabolite trimethylamine N-oxide and cardiovascular diseases. Front Endocrinol (Lausanne). 2023;14:1085041.
pubmed: 36824355
doi: 10.3389/fendo.2023.1085041
Querio G, Antoniotti S, Geddo F, Levi R, Gallo MP. Modulation of endothelial function by TMAO, a gut microbiota-derived metabolite. Int J Mol Sci. 2023;24(6).
Nesci A, Carnuccio C, Ruggieri V, D’Alessandro A, Di Giorgio A, Santoro L, Gasbarrini A, Santoliquido A, Ponziani FR. Gut microbiota and cardiovascular disease: evidence on the metabolic and inflammatory background of a complex relationship. Int J Mol Sci 2023, 24(10).
Al Khodor S, Reichert B, Shatat IF. The Microbiome and Blood pressure: can microbes regulate our blood pressure? Front Pediatr. 2017;5:138.
pubmed: 28674682
pmcid: 5474689
doi: 10.3389/fped.2017.00138
Wei J, Zhang Y, Dalbeth N, Terkeltaub R, Yang T, Wang Y, Yang Z, Li J, Wu Z, Zeng C, et al. Association between gut microbiota and elevated serum urate in two independent cohorts. Arthritis Rheumatol. 2022;74(4):682–91.
pubmed: 34725964
doi: 10.1002/art.42009
Zhao D, Cui H, Shao Z, Cao L. Abdominal obesity, chronic inflammation and the risk of non-alcoholic fatty liver disease. Ann Hepatol. 2023;28(4):100726.
pubmed: 35636732
doi: 10.1016/j.aohep.2022.100726
Gutierrez-Cuevas J, Santos A, Armendariz-Borunda J. Pathophysiological molecular mechanisms of obesity: a link between MAFLD and NASH with cardiovascular diseases. Int J Mol Sci 2021, 22(21).
Dao AD, Nguyen VH, Ito T, Cheung R, Nguyen MH. Prevalence, characteristics, and mortality outcomes of obese and nonobese MAFLD in the United States. Hepatol Int. 2023;17(1):225–36.
pubmed: 36309601
doi: 10.1007/s12072-022-10436-2
Pipitone RM, Ciccioli C, Infantino G, La Mantia C, Parisi S, Tulone A, Pennisi G, Grimaudo S, Petta S. MAFLD: a multisystem disease. Ther Adv Endocrinol Metab. 2023;14:20420188221145549.
pubmed: 36726391
pmcid: 9885036
doi: 10.1177/20420188221145549
Finney AC, Das S, Kumar D, McKinney MP, Cai B, Yurdagul A Jr., Rom O. The interplay between nonalcoholic fatty liver disease and atherosclerotic cardiovascular disease. Front Cardiovasc Med. 2023;10:1116861.
pubmed: 37200978
pmcid: 10185914
doi: 10.3389/fcvm.2023.1116861
McCullough A, Previs SF, Dasarathy J, Lee K, Osme A, Kim C, Ilchenko S, Lorkowski SW, Smith JD, Dasarathy S, et al. HDL flux is higher in patients with nonalcoholic fatty liver disease. Am J Physiol Endocrinol Metab. 2019;317(5):E852–62.
pubmed: 31503515
pmcid: 6879863
doi: 10.1152/ajpendo.00193.2019
Golubeva JA, Sheptulina AF, Elkina AY, Liusina EO, Kiselev AR, Drapkina OM. Which comes first, nonalcoholic fatty liver disease or arterial hypertension? Biomedicines 2023, 11(9).
Sata Y, Head GA, Denton K, May CN, Schlaich MP. Role of the sympathetic nervous system and its modulation in renal hypertension. Front Med. 2018;5:82.
doi: 10.3389/fmed.2018.00082
Zhao YC, Zhao GJ, Chen Z, She ZG, Cai J, Li H. Nonalcoholic fatty liver disease: an emerging driver of hypertension. Hypertension. 2020;75(2):275–84.
pubmed: 31865799
doi: 10.1161/HYPERTENSIONAHA.119.13419
Yiannikouris F, Gupte M, Putnam K, Thatcher S, Charnigo R, Rateri DL, Daugherty A, Cassis LA. Adipocyte deficiency of angiotensinogen prevents obesity-induced hypertension in male mice. Hypertension. 2012;60(6):1524–30.
pubmed: 23108647
doi: 10.1161/HYPERTENSIONAHA.112.192690
Musso G, Saba F, Cassader M, Paschetta E, De Michieli F, Pinach S, Framarin L, Berrutti M, Leone N, Parente R, et al. Angiotensin II type 1 receptor rs5186 gene variant predicts Incident NAFLD and Associated hypertension: role of dietary fat-induced pro-inflammatory cell activation. Am J Gastroenterol. 2019;114(4):607–19.
pubmed: 30920415
doi: 10.14309/ajg.0000000000000154
Cho IJ, Oh DH, Yoo J, Hwang YC, Ahn KJ, Chung HY, Jeong SW, Moon JY, Lee SH, Lim SJ, et al. Allopurinol ameliorates high fructose diet induced hepatic steatosis in diabetic rats through modulation of lipid metabolism, inflammation, and ER stress pathway. Sci Rep. 2021;11(1):9894.
pubmed: 33972568
pmcid: 8110790
doi: 10.1038/s41598-021-88872-7
Zhou XD, Cai J, Targher G, Byrne CD, Shapiro MD, Sung KC, Somers VK, Chahal CAA, George J, Chen LL, et al. Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention. Cardiovasc Diabetol. 2022;21(1):270.
pubmed: 36463192
pmcid: 9719631
doi: 10.1186/s12933-022-01697-0
Koutentakis M, Kucinski J, Swieczkowski D, Surma S, Filipiak KJ, Gasecka A. The ketogenic effect of SGLT-2 inhibitors-beneficial or harmful? J Cardiovasc Dev Dis 2023, 10(11).
Stepanova M, Rafiq N, Younossi ZM. Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study. Gut. 2010;59(10):1410–5.
pubmed: 20660697
doi: 10.1136/gut.2010.213553
Koehler EM, Plompen EP, Schouten JN, Hansen BE, Darwish Murad S, Taimr P, Leebeek FW, Hofman A, Stricker BH, Castera L, et al. Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: the Rotterdam study. Hepatology. 2016;63(1):138–47.
pubmed: 26171685
doi: 10.1002/hep.27981
Koulaouzidis G, Charisopoulou D, Kukla M, Marlicz W, Rydzewska G, Koulaouzidis A, Skonieczna-Zydecka K. Association of non-alcoholic fatty liver disease with coronary artery calcification progression: a systematic review and meta-analysis. Prz Gastroenterol. 2021;16(3):196–206.
pubmed: 34584580
pmcid: 8456760
Sung KC, Yoo TK, Lee MY, Byrne CD, Zheng MH, Targher G. Comparative associations of nonalcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease with coronary artery calcification: a cross-sectional and longitudinal cohort study. Arterioscler Thromb Vasc Biol. 2023;43(3):482–91.
pubmed: 36727522
doi: 10.1161/ATVBAHA.122.318661
Chen S, Xue H, Huang R, Chen K, Zhang H, Chen X. Associations of MAFLD and MAFLD subtypes with the risk of the incident myocardial infarction and stroke. Diabetes Metab. 2023;49(5):101468.
pubmed: 37586479
doi: 10.1016/j.diabet.2023.101468
Peng D, Yu Z, Wang M, Shi J, Sun L, Zhang Y, Zhao W, Chen C, Tang J, Wang C, et al. Association of metabolic dysfunction-associated fatty liver disease with left ventricular diastolic function and cardiac morphology. Front Endocrinol. 2022;13:935390.
doi: 10.3389/fendo.2022.935390
Wei Z, Huang Z, Song Z, Zhao W, Zhao D, Tan Y, Chen S, Yang P, Li Y, Wu S. Metabolic dysfunction-associated fatty liver disease and incident heart failure risk: the Kailuan cohort study. Diabetol Metab Syndr. 2023;15(1):137.
pubmed: 37355613
pmcid: 10290295
doi: 10.1186/s13098-023-01102-0
Wu S, Li Y, Zhang Y, Su X, Zuo Y, Chen G, Xu G, Chen S, He Y, Wang A. Sex and age differences in the Association between Metabolic Dysfunction-Associated fatty liver disease and heart failure: a prospective cohort study. Circ Heart Fail. 2024;17(2):e010841.
pubmed: 38348678
doi: 10.1161/CIRCHEARTFAILURE.123.010841
Lei F, Qin JJ, Song X, Liu YM, Chen MM, Sun T, Huang X, Deng KQ, Zuo X, Yao D, et al. The prevalence of MAFLD and its association with atrial fibrillation in a nationwide health check-up population in China. Front Endocrinol (Lausanne). 2022;13:1007171.
pubmed: 36237179
doi: 10.3389/fendo.2022.1007171
Keskin M, Hayiroglu MI, Uzun AO, Guvenc TS, Sahin S, Kozan O. Effect of nonalcoholic fatty liver disease on in-hospital and long-term outcomes in patients with ST-segment elevation myocardial infarction. Am J Cardiol. 2017;120(10):1720–6.
pubmed: 28867124
doi: 10.1016/j.amjcard.2017.07.107
Xie W, Gan J, Zhou X, Tian H, Pan X, Liu W, Li X, Du J, Xu A, Zheng M, et al. Myocardial infarction accelerates the progression of MASH by triggering immunoinflammatory response and induction of periosti. Cell Metab. 2024;36(6):1269–e12861269.
pubmed: 38838640
doi: 10.1016/j.cmet.2024.04.020
Mantovani A, Dauriz M, Sandri D, Bonapace S, Zoppini G, Tilg H, Byrne CD, Targher G. Association between non-alcoholic fatty liver disease and risk of atrial fibrillation in adult individuals: an updated meta-analysis. Liver Int. 2019;39(4):758–69.
pubmed: 30657626
doi: 10.1111/liv.14044
van Kleef LA, Lu Z, Ikram MA, de Groot NMS, Kavousi M, de Knegt RJ. Liver stiffness not fatty liver disease is associated with atrial fibrillation: the Rotterdam study. J Hepatol. 2022;77(4):931–8.
pubmed: 35688226
doi: 10.1016/j.jhep.2022.05.030
Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol. 2008;48(5):835–47.
pubmed: 18334275
doi: 10.1016/j.jhep.2008.02.008
Myers RP, Elkashab M, Ma M, Crotty P, Pomier-Layrargues G. Transient elastography for the noninvasive assessment of liver fibrosis: a multicentre Canadian study. Can J Gastroenterol. 2010;24(11):661–70.
pubmed: 21157581
pmcid: 3004419
Liver, EAftSot. Hígado ALpeEd: EASL-ALEH clinical practice guidelines: non-invasive tests for evalution of liver disease severity and prognosis. J Hepatol. 2015;63:237–64.
doi: 10.1016/j.jhep.2015.04.006
Boeckmans J, Sandrin L, Knackstedt C, Schattenberg JM. Liver stiffness as a cornerstone in heart disease risk assessment. Liver Int. 2024;44(2):344–56.
pubmed: 38014628
doi: 10.1111/liv.15801
Nightingale K. Acoustic radiation force impulse (ARFI) imaging: a review. Curr Med Imaging Rev. 2011;7(4):328–39.
pubmed: 22545033
pmcid: 3337770
doi: 10.2174/157340511798038657
Alem SA, Abdellatif Z, Mabrouk M, Zayed N, Elsharkawy A, Khairy M, Musa S, Anwar I, Yosry A. Diagnostic accuracy of acoustic radiation force impulse elastography (ARFI) in comparison to other non-invasive modalities in staging of liver fibrosis in chronic HCV patients: single-center experience. Abdom Radiol (NY). 2019;44(8):2751–8.
pubmed: 31028432
doi: 10.1007/s00261-019-02031-1
Vidili G, Arru M, Meloni P, Solinas G, Atzori S, Maida I. Comparison of 2D Shear Wave Elastography and transient elastography in non-invasive evaluation of liver fibrosis in Hepatitis C Virus-Related Chronic Liver Disease. J Clin Med 2024, 13(14).
Erre GL, Cadoni ML, Meloni P, Castagna F, Mangoni AA, Piga M, Passiu G, Carru C, Zinellu A, Vidili G. Methotrexate therapy is not associated with increased liver stiffness and significant liver fibrosis in rheumatoid arthritis patients: a cross-sectional controlled study with real-time two-dimensional shear wave elastography. Eur J Intern Med. 2019;69:57–63.
pubmed: 31474422
doi: 10.1016/j.ejim.2019.08.022
Erre GL, Castagna F, Sauchella A, Meloni P, Mangoni AA, Farina G, Woodman R, Dore MP, Vidili G. Prevalence and risk factors of moderate to severe hepatic steatosis in patients with rheumatoid arthritis: an ultrasonography cross-sectional case-control study. Ther Adv Musculoskelet Dis. 2021;13:1759720X211042739.
pubmed: 34819999
pmcid: 8606981
doi: 10.1177/1759720X211042739
Dulai PS, Sirlin CB, Loomba R. MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: clinical trials to clinical practice. J Hepatol. 2016;65(5):1006–16.
pubmed: 27312947
pmcid: 5124376
doi: 10.1016/j.jhep.2016.06.005
Thomas Elgeti MB, Hamm B. Ju¨rgen Braun, and Ingolf Sack: <2010 Cardiac magnetic resonance Elastography toward the diagnosis of abnormal myocardial Relaxation.pdf>. Invest Radiol. 2010;45(12):782–7.
pubmed: 20829709
Park CC, Nguyen P, Hernandez C, Bettencourt R, Ramirez K, Fortney L, Hooker J, Sy E, Savides MT, Alquiraish MH, et al. Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease. Gastroenterology. 2017;152(3):598–e607592.
pubmed: 27911262
doi: 10.1053/j.gastro.2016.10.026
AlShaalan R, Aljiffry M, Al-Busafi S, Metrakos P, Hassanain M. Nonalcoholic fatty liver disease: noninvasive methods of diagnosing hepatic steatosis. Saudi J Gastroenterol. 2015;21(2):64–70.
pubmed: 25843191
pmcid: 4392577
doi: 10.4103/1319-3767.153812
van Ewijk PA, Schrauwen-Hinderling VB, Bekkers SC, Glatz JF, Wildberger JE, Kooi ME. MRS: a noninvasive window into cardiac metabolism. NMR Biomed. 2015;28(7):747–66.
pubmed: 26010681
doi: 10.1002/nbm.3320
Iqra Nadeem Kazi M, Lily Kuo M, Eugenia Tsai M. Noninvasive methods for assessing liver fibrosis and Steatosis. Gastroenterol Hepatol 2024, 20(1).
Ciardullo S, Cannistraci R, Muraca E, Zerbini F, Perseghin G. Liver fibrosis, NT-ProBNP and mortality in patients with MASLD: a population-based cohort study. Nutr Metab Cardiovasc Dis. 2024;34(4):963–71.
pubmed: 38161125
doi: 10.1016/j.numecd.2023.11.011
Vieira Barbosa J, Milligan S, Frick A, Broestl J, Younossi Z, Afdhal N, Lai M. Fibrosis-4 Index can independently predict major adverse Cardiovascular events in nonalcoholic fatty liver disease. Am J Gastroenterol. 2022;117(3):453–61.
pubmed: 35041626
doi: 10.14309/ajg.0000000000001606
Durak H, Çetin M, Emlek N, Ergül E, Özyıldız AG, Öztürk M, Duman H, Yılmaz AS, Şatıroğlu Ö. FIB-4 liver fibrosis index correlates with aortic valve sclerosis in non-alcoholic population. 2024, 41(1):e15732.
Shibata N, Ito T, Toyoda H, Tanaka A, Morita Y, Kanzaki Y, Watanabe N, Yoshioka N, Morishima I. Predictability of noninvasive liver fibrosis score for cardiac events in patients with nonalcoholic fatty liver disease. Eur Heart J 2023, 44(Supplement_2).
Lee J, Vali Y, Boursier J, Spijker R, Anstee QM, Bossuyt PM, Zafarmand MH. Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: a systematic review. Liver Int. 2021;41(2):261–70.
pubmed: 32946642
pmcid: 7898346
doi: 10.1111/liv.14669
Ballestri S, Mantovani A, Baldelli E, Lugari S, Maurantonio M, Nascimbeni F, Marrazzo A, Romagnoli D, Targher G, Lonardo A. Liver Fibrosis Biomarkers Accurately Exclude Advanced Fibrosis and Are Associated with Higher Cardiovascular Risk Scores in Patients with NAFLD or Viral Chronic Liver Disease. Diagnostics (Basel) 2021, 11(1).
van der Bijl P, Kuneman JH, Bax JJ. Pericoronary adipose tissue attenuation: diagnostic and prognostic implications. Eur Heart J Cardiovasc Imaging. 2022;23(12):e537–8.
pubmed: 36069116
doi: 10.1093/ehjci/jeac175
Yuvaraj J, Lin A, Nerlekar N, Munnur RK, Cameron JD, Dey D, Nicholls SJ, Wong DTL. Pericoronary Adipose tissue attenuation is Associated with High-Risk Plaque and subsequent Acute Coronary Syndrome in patients with stable coronary artery disease. Cells 2021, 10(5).
Takahata Y, Takahashi A, Anzai Y, Abe N, Sugaya T, Fujita M, Hayashi M, Abe K, Ohira H. Lifestyle factors affecting new-onset nonalcoholic fatty liver disease. Prev Med Rep. 2024;37:102577.
pubmed: 38282666
doi: 10.1016/j.pmedr.2023.102577
Promrat K, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, Wands JR, Fava JL, Wing RR. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology. 2010;51(1):121–9.
pubmed: 19827166
doi: 10.1002/hep.23276
Niederseer D, Wernly B, Aigner E, Stickel F, Datz C. NAFLD and cardiovascular diseases: epidemiological, mechanistic and therapeutic considerations. J Clin Med. 2021;10(3).
Akhavan Rezayat A, Dadgar Moghadam M, Ghasemi Nour M, Shirazinia M, Ghodsi H, Rouhbakhsh Zahmatkesh MR, Tavakolizadeh Noghabi M, Hoseini B, Akhavan Rezayat K. Association between smoking and non-alcoholic fatty liver disease: a systematic review and meta-analysis. SAGE Open Med. 2018;6:2050312117745223.
pubmed: 29399359
pmcid: 5788091
doi: 10.1177/2050312117745223
Laursen TL, Hagemann CA, Wei C, Kazankov K, Thomsen KL, Knop FK, Gronbaek H. Bariatric surgery in patients with non-alcoholic fatty liver disease - from pathophysiology to clinical effects. World J Hepatol. 2019;11(2):138–49.
pubmed: 30820265
pmcid: 6393715
doi: 10.4254/wjh.v11.i2.138
Stefan N, Haring HU, Cusi K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabetes Endocrinol. 2019;7(4):313–24.
pubmed: 30174213
doi: 10.1016/S2213-8587(18)30154-2
Quinn CE, Hamilton PK, Lockhart CJ, McVeigh GE. Thiazolidinediones: effects on insulin resistance and the cardiovascular system. Br J Pharmacol. 2008;153(4):636–45.
pubmed: 17906687
doi: 10.1038/sj.bjp.0707452
Guru B, Tamrakar AK, Manjula SN, Prashantha Kumar BR. Novel dual PPARalpha/gamma agonists protect against liver steatosis and improve insulin sensitivity while avoiding side effects. Eur J Pharmacol. 2022;935:175322.
pubmed: 36228743
doi: 10.1016/j.ejphar.2022.175322
Mao T, Zhang C, Yang S, Bi Y, Li M, Yu J. Semaglutide alters gut microbiota and improves NAFLD in db/db mice. Biochem Biophys Res Commun. 2024;710:149882.
pubmed: 38583231
doi: 10.1016/j.bbrc.2024.149882
Cheung KS, Ng HY, Hui RWH, Lam LK, Mak LY, Ho YC, Tan JT, Chan EW, Seto WK, Yuen MF et al. Effects of empagliflozin on liver fat in patients with metabolic dysfunction-associated steatotic liver disease without diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Hepatology 2024.
Sumida Y, Naito Y, Tanaka S, Sakai K, Inada Y, Taketani H, Kanemasa K, Yasui K, Itoh Y, Okanoue T, et al. Long-term (> = 2 year) efficacy of vitamin E for non-alcoholic steatohepatitis. Hepatogastroenterology. 2013;60(126):1445–50.
pubmed: 23933938
Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, Chalasani N, Dasarathy S, Diehl AM, Hameed B, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015;385(9972):956–65.
pubmed: 25468160
doi: 10.1016/S0140-6736(14)61933-4
Loomba R, Hartman ML, Lawitz EJ, Vuppalanchi R, Boursier J, Bugianesi E, Yoneda M, Behling C, Cummings OW, Tang Y, et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med. 2024;391(4):299–310.
pubmed: 38856224
doi: 10.1056/NEJMoa2401943
Petta S, Targher G, Romeo S, Pajvani UB, Zheng MH, Aghemo A, Valenti LVC. The first MASH drug therapy on the horizon: current perspectives of resmetirom. Liver Int 2024.
Loomba R, Sanyal AJ, Kowdley KV, Bhatt DL, Alkhouri N, Frias JP, Bedossa P, Harrison SA, Lazas D, Barish R, et al. Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH. N Engl J Med. 2023;389(11):998–1008.
pubmed: 37356033
pmcid: 10718287
doi: 10.1056/NEJMoa2304286
Sanyal AJ, Bedossa P, Fraessdorf M, Neff GW, Lawitz E, Bugianesi E, Anstee QM, Hussain SA, Newsome PN, Ratziu V, et al. A phase 2 randomized trial of survodutide in MASH and fibrosis. N Engl J Med. 2024;391(4):311–9.
pubmed: 38847460
doi: 10.1056/NEJMoa2401755
Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, Prescott E, Storey RF, Deaton C, Cuisset T, et al. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407–77.
pubmed: 31504439
doi: 10.1093/eurheartj/ehz425
Simon TG, Henson J, Osganian S, Masia R, Chan AT, Chung RT, Corey KE. Daily aspirin use associated with reduced risk for fibrosis progression in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2019;17(13):2776-e27842774.
pubmed: 31077838
pmcid: 6842070
doi: 10.1016/j.cgh.2019.04.061
Ballestri S, Capitelli M, Fontana MC, Arioli D, Romagnoli E, Graziosi C, Lonardo A, Marietta M, Dentali F, Cioni G. Direct oral anticoagulants in patients with liver disease in the era of non-alcoholic fatty liver disease global epidemic: a narrative review. Adv Ther. 2020;37(5):1910–32.
pubmed: 32285340
pmcid: 7467481
doi: 10.1007/s12325-020-01307-z
Pastori D, Polimeni L, Baratta F, Pani A, Del Ben M, Angelico F. The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease. Dig Liver Dis. 2015;47(1):4–11.
pubmed: 25224698
doi: 10.1016/j.dld.2014.07.170
Pastori D, Pani A, Di Rocco A, Menichelli D, Gazzaniga G, Farcomeni A, D’Erasmo L, Angelico F, Del Ben M, Baratta F. Statin liver safety in non-alcoholic fatty liver disease: a systematic review and metanalysis. Br J Clin Pharmacol. 2022;88(2):441–51.
pubmed: 34133035
doi: 10.1111/bcp.14943
Ryoo JH, Suh YJ, Shin HC, Cho YK, Choi JM, Park SK. Clinical association between non-alcoholic fatty liver disease and the development of hypertension. J Gastroenterol Hepatol. 2014;29(11):1926–31.
pubmed: 24910023
doi: 10.1111/jgh.12643
Aneni EC, Oni ET, Martin SS, Blaha MJ, Agatston AS, Feldman T, Veledar E, Conceicao RD, Carvalho JA, Santos RD, et al. Blood pressure is associated with the presence and severity of nonalcoholic fatty liver disease across the spectrum of cardiometabolic risk. J Hypertens. 2015;33(6):1207–14.
pubmed: 25693058
doi: 10.1097/HJH.0000000000000532
Li Y, Xu H, Wu W, Ye J, Fang D, Shi D, Li L. Clinical application of angiotensin receptor blockers in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis. Oncotarget. 2018;9(35):24155–67.
pubmed: 29844879
pmcid: 5963622
doi: 10.18632/oncotarget.23816